IQCG: A Potential Drug Target Or Biomarker for Cancer (G84223)

Target Name: IQCG

NCBI ID: G84223

IQCG

IQCG: A Potential Drug Target Or Biomarker for Cancer

IQCG (Integrin-Like Protein Glycoprotein) is a protein that is expressed in many different tissues throughout the body. It is a type of transmembrane protein that is involved in many different cellular processes, including cell adhesion, migration, and signaling. IQCG has also been shown to play a role in the development and progression of various diseases, including cancer.

One of the key features of IQCG is its ability to interact with integrins, which are a type of protein that is found on the surface of many different cells. Integrins are involved in many different cellular processes, including cell adhesion, migration, and signaling. IQCG has been shown to interact with integrins on the surface of cancer cells, which could make it a potential drug target or biomarker for cancer.

In addition to its role in cell adhesion and migration, IQCG has also been shown to play a role in the development and progression of various diseases, including cancer. For example, studies have shown that IQCG is often overexpressed in many types of cancer, which could make it a potential biomarker for these diseases.

Another potential use for IQCG is as a drug target. By interacting with integrins on the surface of cancer cells, IQCG could potentially be used to inhibit the growth and spread of these cells. This could be done through a variety of different mechanisms, including blocking the formation of new blood vessels that supply the cancer cells with the oxygen and nutrients they need to grow, or by inhibiting the ability of the cancer cells to stick to the blood vessels that supply them.

IQCG is also a potential biomarker for tracking the progress of cancer treatments. By measuring the levels of IQCG in the blood or other body fluids, doctors can track the effectiveness of different treatments and determine when a patient may need to be re- treated. This could be especially important in the case of cancer, where treatment outcomes can vary widely from one patient to another.

Overall, IQCG is a protein that has the potential to be a drug target or biomarker for a variety of different diseases, including cancer. Its ability to interact with integrins and its involvement in the development and progression of various diseases make it a promising candidate for these roles. Further research is needed to fully understand the role of IQCG in these processes and to develop effective treatments.

Protein Name: IQ Motif Containing G

Functions: Component of the nexin-dynein regulatory complex (N-DRC), a key regulator of ciliary/flagellar motility which maintains the alignment and integrity of the distal axoneme and regulates microtubule sliding in motile axonemes. Binds calmodulin when cellular Ca(2+) levels are low and thereby contributes to the regulation of calcium and calmodulin-dependent protein kinase IV (CAMK4) activity; contributes to the regulation of CAMK4 signaling cascades. Required for normal axoneme assembly in sperm flagella, normal sperm tail formation and for male fertility

The "IQCG Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IQCG comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets